Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis
NCT07521332Phase 4Recruiting
- Sponsor
- Asian Institute of Medical Sciences
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban in Cirrhosis, Portal Hypertension (PH), sponsored by Asian Institute of Medical Sciences. Started Apr 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT07521332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521332.